ASP6432, a type 1 lysophosphatidic acid receptor antagonist, reduces urethral function during urine voiding and improves voiding dysfunction.
Animals
Female
Male
NG-Nitroarginine Methyl Ester
/ pharmacology
Nitric Oxide Synthase
/ antagonists & inhibitors
Rats
Rats, Sprague-Dawley
Rats, Wistar
Receptors, Adrenergic, alpha-1
/ metabolism
Receptors, Lysophosphatidic Acid
/ antagonists & inhibitors
Tamsulosin
/ pharmacology
Urethra
/ drug effects
Urinary Bladder
/ drug effects
Urinary Bladder Diseases
/ drug therapy
Urine
/ physiology
LPA(1)
Lower urinary tract symptoms
Lysophosphatidic acid
Nitric oxide
Urethra
Urine voiding
Journal
European journal of pharmacology
ISSN: 1879-0712
Titre abrégé: Eur J Pharmacol
Pays: Netherlands
ID NLM: 1254354
Informations de publication
Date de publication:
15 Mar 2019
15 Mar 2019
Historique:
received:
15
09
2018
revised:
11
01
2019
accepted:
14
01
2019
pubmed:
19
1
2019
medline:
5
6
2019
entrez:
19
1
2019
Statut:
ppublish
Résumé
Current pharmacotherapies for voiding dysfunctions are in need of improvement. Lysophosphatidic acid (LPA) is a phospholipid that contracts the urethra by activating type 1 LPA receptors (LPA
Identifiants
pubmed: 30658116
pii: S0014-2999(19)30022-6
doi: 10.1016/j.ejphar.2019.01.014
pii:
doi:
Substances chimiques
Receptors, Adrenergic, alpha-1
0
Receptors, Lysophosphatidic Acid
0
Nitric Oxide Synthase
EC 1.14.13.39
Tamsulosin
G3P28OML5I
NG-Nitroarginine Methyl Ester
V55S2QJN2X
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
83-90Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.